ncRNA basic information
ncRNA ID:
MIMAT0004748
ncRNA Database:
miRBase
ncRNA Name:
miR-423-5p
ncRNA Type:
miRNA
ncRNA Expression:
up-regulated
ncRNA Method:
RT-PCR, qRT-PCR
ncRNA Target Gene:
ING-4
ncRNA Pathway:
AKT and ERK1/2 pathway
Evidence (ncRNA-drug):
validated
drug basic information
Drug ID:
DB00853 (APRD00557)
Drug Name:
Temozolomide
Drug Method:
Real-time PCR was used to analyze the expression of microRNA-423-5p (miR-423-5p) in human glioma samples and normal brain tissue. Apoptosis, cell cycle, proliferation, immunostaining, transwell, in vitro 2D and 3D migration, and chemosensitivity assays were performed to assess the phenotypic changes in glioma cells overexpressing miRNA-423-5p. Western blotting was used to determine the expression of inhibitor of growth 4 (ING-4)in glioma tissues, and a luciferase reporter assay was conducted to confirm whether ING-4 is a direct target of miR-423-5p. Western blotting was used to identify the potential signaling pathways that are affected in glioma cell growth by miR-423-5p. Xenograft tumors were examined in vivo for the carcinogenic effects of miR-423-5p in glioma tissues.
Drug Response:
resistant
Cancer basic information
Cancer:
glioblastoma
Tissue/Cell:
cell line (U87 and U251)
Other information
Title:
miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas.
Journal:
Neuro Oncol
Published:
2017
PubMed ID:
27471108